Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dechra announces “groundbreaking” strangles vaccine
"We are sure that the new strangles vaccine will be a vital tool in disease prevention and a huge benefit to the equestrian industry" - Sara Barker, Dechra.

Protein-based tool is available for horses and ponies.

Dechra Veterinary Products has announced a "groundbreaking" vaccine to protect horses and ponies against strangles.

Developed over 25 years, Strangvac is the first and only intramuscular vaccine for strangles - a highly contagious disease caused by the Streptococcus equi bacterium.

The new vaccine contains recombinant proteins from Streptococcus equi and features DIVA (Differentiating Infected from Vaccinated Animals) capability. It possesses no live bacteria or bacterial DNA, nor will it trigger a positive result in PCR or culture tests.

Strangvac is proven effective in more than 94 per cent of horses, reducing the clinical signs of strangles, including high temperature, coughing. Difficulty swallowing and inappetance. It can be administered to foals from the age of five months, with two injections given at a four-week interval.

The manufacturer states that horses at high risk of Streptococcus equi should be re-vaccinated after two months, such as those in livery. Immunological memory was found in horses following repeated vaccination six months after primary vaccination.

Strangvac has been made possible thanks to more than €20million of funding from the Animal Health Trust and, more recently, the Swedish company Intervacc AB. 

Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, comments: “Strangvac is a groundbreaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”

Sara Barker, equine field support manager at Dechra, added: “Strangles is highly contagious and is one of the most common equine respiratory diseases with an estimated 600 outbreaks each year in the UK alone. Feared by horse owners due to the potential severity of clinical signs and the infectious nature of strangles, we are sure that the new strangles vaccine will be a vital tool in disease prevention and a huge benefit to the equestrian industry as a whole.”

Further information about the vaccine is available from Dechra territory sales managers.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.